A Phase I/II Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Zhejiang Anglikang Pharmaceutical Co., Ltd.
National Institutes of Health Clinical Center (CC)
Mayo Clinic
City of Hope Medical Center
Binhui Biopharmaceutical Co., Ltd.
City of Hope Medical Center
Fox Chase Cancer Center
M.D. Anderson Cancer Center
ProgenaBiome
Apollomics Inc.
Allarity Therapeutics
University of California, Davis
Mabwell (Shanghai) Bioscience Co., Ltd.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Open Innovation Partners, Inc.
Oshadi Drug Administration
Institut Claudius Regaud
Piramal Enterprises Limited
Piramal Enterprises Limited
GlaxoSmithKline
European Organisation for Research and Treatment of Cancer - EORTC
Southern Europe New Drug Organization
Metastatix, Inc.